EDIL3 and prostate carcinoma: In prostate cancer, out of 28 low-grade (Gleason ≤ 7) prostate tumors, 20 (71.4%) expressed low levels of EDIL3, while out of 23 high-grade (Gleason 8–10) prostate tumors, 20 (87%) expressed high levels of EDIL3 (Fig. 2e).